Screener
Enliven Therapeutics ELVN Total Operating Expenses
Total Operating Expenses at other companies
Other financials
Where this comes from
Reported directly by Enliven Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The source filing: Enliven Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:17 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211982
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development | $20,687 | $24,895 |
| General and administrative | 7,136 | 6,798 |
| Total operating expenses | 27,823 | 31,693 |
| Loss from operations | (27,823) | (31,693) |
| Other income (expense), net | ||
| Interest income | 4,196 | 3,196 |
| Other expense | — | (47) |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Enliven Therapeutics's total operating expenses?
- Enliven Therapeutics (ELVN) reported total operating expenses of $27.82M in Q1 2026.
- How has Enliven Therapeutics's total operating expenses changed year-over-year?
- Enliven Therapeutics's total operating expenses decreased by 12.2% year-over-year, from $31.69M to $27.82M.
- What is the long-term trend for Enliven Therapeutics's total operating expenses?
- Over 4 years (2021 to 2025), Enliven Therapeutics's total operating expenses has grown at a 23.5% compound annual growth rate (CAGR), from $51.44M to $119.66M.
- What does total operating expenses mean?
- The sum of all operating costs including COGS, SG&A, R&D, D&A, and other operating charges. Revenue minus total operating expenses equals operating income.
Ask your AI about Enliven Therapeutics's total operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude